Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
Clinical trial NCT02315703 · COMPLETED
Trial details
- NCT number
- NCT02315703
- Sponsor
- Janssen Vaccines & Prevention B.V.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-22
- Primary completion
- 2017-08-29
- Enrollment
- 393
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.